Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 66

1.

Genetic polymorphisms associated with oxaliplatin-induced peripheral neurotoxicity in Japanese patients with colorectal cancer.

Oguri T, Mitsuma A, Inada-Inoue M, Morita S, Shibata T, Shimokata T, Sugishita M, Nakayama G, Uehara K, Hasegawa Y, Ando Y.

Int J Clin Pharmacol Ther. 2013 Jun;51(6):475-81. doi: 10.5414/CP201851.

PMID:
23547850
2.

Polymorphic markers associated with severe oxaliplatin-induced, chronic peripheral neuropathy in colon cancer patients.

Won HH, Lee J, Park JO, Park YS, Lim HY, Kang WK, Kim JW, Lee SY, Park SH.

Cancer. 2012 Jun 1;118(11):2828-36. doi: 10.1002/cncr.26614. Epub 2011 Oct 21.

3.

Genetic determinants of chronic oxaliplatin-induced peripheral neurotoxicity: a genome-wide study replication and meta-analysis.

Terrazzino S, Argyriou AA, Cargnin S, Antonacopoulou AG, Briani C, Bruna J, Velasco R, Alberti P, Campagnolo M, Lonardi S, Cortinovis D, Cazzaniga M, Santos C, Kalofonos HP, Canonico PL, Genazzani AA, Cavaletti G.

J Peripher Nerv Syst. 2015 Mar;20(1):15-23. doi: 10.1111/jns.12110.

PMID:
25858589
4.

Associations between oxaliplatin-induced peripheral neuropathy and polymorphisms of the ERCC1 and GSTP1 genes.

Inada M, Sato M, Morita S, Kitagawa K, Kawada K, Mitsuma A, Sawaki M, Fujita K, Ando Y.

Int J Clin Pharmacol Ther. 2010 Nov;48(11):729-34.

PMID:
20979931
5.

Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: results from a prospective multicenter study.

Argyriou AA, Cavaletti G, Antonacopoulou A, Genazzani AA, Briani C, Bruna J, Terrazzino S, Velasco R, Alberti P, Campagnolo M, Lonardi S, Cortinovis D, Cazzaniga M, Santos C, Psaromyalou A, Angelopoulou A, Kalofonos HP.

Cancer. 2013 Oct 1;119(19):3570-7. doi: 10.1002/cncr.28234. Epub 2013 Jul 2.

6.

The combination of ERCC1 and XRCC1 gene polymorphisms better predicts clinical outcome to oxaliplatin-based chemotherapy in metastatic colorectal cancer.

Liang J, Jiang T, Yao RY, Liu ZM, Lv HY, Qi WW.

Cancer Chemother Pharmacol. 2010 Aug;66(3):493-500. doi: 10.1007/s00280-009-1186-3. Epub 2009 Dec 4.

PMID:
19960344
7.

Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients.

Kweekel DM, Gelderblom H, Antonini NF, Van der Straaten T, Nortier JW, Punt CJ, Guchelaar HJ.

Eur J Cancer. 2009 Mar;45(4):572-8. doi: 10.1016/j.ejca.2008.10.015. Epub 2008 Dec 10.

PMID:
19084393
8.
9.

The effect of monosialotetrahexosylganglioside (GM1) in prevention of oxaliplatin induced neurotoxicity: a retrospective study.

Chen XF, Wang R, Yin YM, Røe OD, Li J, Zhu LJ, Guo RH, Wu T, Shu YQ.

Biomed Pharmacother. 2012 Jun;66(4):279-84. doi: 10.1016/j.biopha.2012.01.002. Epub 2012 Feb 17.

PMID:
22397758
10.

Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy.

Ruzzo A, Graziano F, Loupakis F, Rulli E, Canestrari E, Santini D, Catalano V, Ficarelli R, Maltese P, Bisonni R, Masi G, Schiavon G, Giordani P, Giustini L, Falcone A, Tonini G, Silva R, Mattioli R, Floriani I, Magnani M.

J Clin Oncol. 2007 Apr 1;25(10):1247-54. Erratum in: J Clin Oncol. 2009 Jul 1;27(19):3262.

PMID:
17401013
11.

Single nucleotide polymorphisms in nucleotide excision repair genes XPA, XPD, XPG and ERCC1 in advanced colorectal cancer patients treated with first-line oxaliplatin/fluoropyrimidine.

Monzo M, Moreno I, Navarro A, Ibeas R, Artells R, Gel B, Martinez F, Moreno J, Hernandez R, Navarro-Vigo M.

Oncology. 2007;72(5-6):364-70. doi: 10.1159/000113534. Epub 2008 Jan 17.

PMID:
18204222
12.

Associations between glutathione S-transferase pi Ile105Val and glyoxylate aminotransferase Pro11Leu and Ile340Met polymorphisms and early-onset oxaliplatin-induced neuropathy.

Kanai M, Yoshioka A, Tanaka S, Nagayama S, Matsumoto S, Nishimura T, Niimi M, Teramukai S, Takahashi R, Mori Y, Kitano T, Ishiguro H, Yanagihara K, Chiba T, Fukushima M, Matsuda F.

Cancer Epidemiol. 2010 Apr;34(2):189-93. doi: 10.1016/j.canep.2010.02.008. Epub 2010 Mar 21.

13.

Oxaliplatin-induced chronic peripheral neurotoxicity: a prospective analysis in patients with colorectal cancer.

Baek KK, Lee J, Park SH, Park JO, Park YS, Lim HY, Kang WK, Cho YB, Yun SH, Kim HC, Lee WY, Chun HK.

Cancer Res Treat. 2010 Dec;42(4):185-90. doi: 10.4143/crt.2010.42.4.185. Epub 2010 Dec 31.

14.

Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy.

Paré L, Marcuello E, Altés A, del Río E, Sedano L, Salazar J, Cortés A, Barnadas A, Baiget M.

Br J Cancer. 2008 Oct 7;99(7):1050-5. doi: 10.1038/sj.bjc.6604671. Epub 2008 Sep 16. Erratum in: Br J Cancer. 2009 Apr 21;100(8):1368.

15.

Influence of GSTP1 I105V polymorphism on cumulative neuropathy and outcome of FOLFOX-4 treatment in Asian patients with colorectal carcinoma.

Chen YC, Tzeng CH, Chen PM, Lin JK, Lin TC, Chen WS, Jiang JK, Wang HS, Wang WS.

Cancer Sci. 2010 Feb;101(2):530-5. doi: 10.1111/j.1349-7006.2009.01418.x. Epub 2009 Oct 28.

16.

[Clinical features of hypersensitivity reactions to oxaliplatin among Chinese colorectal cancer patients].

Zhao Y, An X, Xiang XJ, Feng F, Wang FH, Wang ZQ, Xu RH, He YJ, Li YH.

Chin J Cancer. 2010 Jan;29(1):102-5. Chinese.

17.

Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer.

Argyriou AA, Cavaletti G, Briani C, Velasco R, Bruna J, Campagnolo M, Alberti P, Bergamo F, Cortinovis D, Cazzaniga M, Santos C, Papadimitriou K, Kalofonos HP.

Cancer. 2013 Jan 15;119(2):438-44. doi: 10.1002/cncr.27732. Epub 2012 Jul 11.

18.

Pharmacogenetic predictors of severe peripheral neuropathy in colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy: a GEMCAD group study.

Custodio A, Moreno-Rubio J, Aparicio J, Gallego-Plazas J, Yaya R, Maurel J, Higuera O, Burgos E, Ramos D, Calatrava A, Andrada E, López R, Moreno V, Madero R, Cejas P, Feliu J.

Ann Oncol. 2014 Feb;25(2):398-403. doi: 10.1093/annonc/mdt546. Epub 2013 Dec 18.

PMID:
24351404
19.

ERCC5 promoter polymorphisms at -763 and +25 predict the response to oxaliplatin-based chemotherapy in patients with advanced colorectal cancer.

Chen J, Xie F, Chen K, Wang D, Jiang H, Li J, Pan F, Chen S, Zhang Y, Ruan Z, Huang H, Zou L, Liang H.

Cancer Biol Ther. 2009 Jul;8(14):1424-30. Epub 2009 Jul 30.

PMID:
19458483
20.

Supplemental Content

Support Center